Back

Assessing the heart failure association international cardio-oncology society risk score for predicting cardiotoxicity in asian breast cancer patients undergoing anthracycline chemotherapy

21 June 2025 (08:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (2) Diagnosis and Management of Cardiovascular Disease in Patients with Cancer CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Doctor Novi Yanti Sari

Siloam Hospitals Group, Jakarta (Indonesia)

59 More presentations in this session

Presentation thumbnail
Temporal trends and emerging burden of cardiovascular disease in cancer patients: A nationwide study from 2005 to 2022
Doctor J. Cho (Daejeon, KR)
Abstract
Presentation thumbnail
Cardiovascular risk factors in oncology: A cross-sectional analysis of patients undergoing chemo-radiotherapy at a tertiary care center
Doctor M. Canavera Ibanez (Bogota, CO)
Abstract Slides
Presentation thumbnail
Incidence of acute cardiovascular hospitalizations and association with hemodynamic biomarkers in cancer patients treated with Immune Checkpoint Inhibitor therapy
Doctor A. Spannbauer (Vienna, AT)
Abstract Slides
Presentation thumbnail
Cardiovascular toxicity prediction in breast cancer patients: the HFA/ICOS risk tool in real-world practice
Doctor B. Andrade (Santarem, PT)
Abstract
Presentation thumbnail
Use of CMR in the assessment of cardiovascular reserve in patients treated with CAR-T therapy
Doctor B. Aumente Rodriguez (Salamanca, ES)
Abstract Slides

Access the full session

Session thumbnail
Poster session (2)

The Event

Event poster

ESC Cardio-Oncology 2025

21 June 2025 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Three-year follow-up of anthracycline-induced cardiotoxicity risk in breast cancer patients using the HFA-ICOS score
thumbnail
Congress Presentation
Cardiovascular toxicity prediction in breast cancer patients: the HFA/ICOS risk tool in real-world practice
thumbnail
Congress Presentation
HEARTOX-P: a novel multiparametric score for predicting cardiotoxicity in HER2-positive breast cancer patients undergoing chemotherapy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources